This month, we cover the latest False Claims Act (FCA) enforcement numbers, the reintroduction of SALSA, and a US Supreme Court case that could impact labs’ FCA liability.

We cover ongoing concerns around polygenic risk scores, new guidance for HPV and cervical cancer screening, and how cheaper genomic testing could affect the clinical testing industry.

This issue shares how potential whistleblowers strengthen your lab’s compliance program and how to avoid retaliation against whistleblowers, as well as how to perform a billing, coding, and reimbursement process compliance audit.

In our latest report, growing consumer and medical debt poses new challenges for patient collections, a new bill would require Medicare to cover breakthrough devices, and Medicare expands coverage of molecular cancer screening tests.